From extending lifespan to bolstering the immune system, the drug’s effects are only just beginning to be understood.
May 2013's selection of notable quotes
May 1, 2013|
PHOTO BY J. CAMERON/WIKIMEDIA COMMONS
—Naturalist Charles Darwin, in a letter to friend and colleague Joseph Hooker, one of many pieces of correspondence between the two biologists that were recently made available online for the first time (January 11, 1844)
—Debra Stewart, president of the Council of Graduate Schools, discussing the effects of sequestration on enrollment in US graduate schools (April 3)
—Terrence Sejnowski, neuroscientist at the
Salk Institute for Biological Studies, on the recently announced Brain Research
through Advancing Innovative Neurotechnologies (BRAIN) Initiative,
to which $100 million is devoted in President Barack Obama’s 2014
budget proposal (April 2)
—Yale University geneticist Francis Ruddle, who produced the first transgenic mouse using viral DNA in 1980 and died on March 10, as quoted in his New York Times obituary (March 20)
— Biologist and Nobel Laureate James Watson, in remarks after a recent public lecture on the role of antioxidants in cancer at the University of California, San Diego (March 21)
—Biochemist and Nobel Laureate Roger Tsien, in reply to questions about a tense exchange he had with Watson at the UC San Diego lecture (March 21)
May 10, 2013
Watson is right. There is a lot of research out there filling in the gaps of knowledge created by initial irrelevant experiments. This herding towards safe money eventually produces a lot of paper but little of worth. It ends up being an embarassment that I can no longer defend as a member of the scientific community.
May 11, 2013
I agree with Watson. The reason is we do in science what we can, not what we need to do due to the difficulties of obtaining funding for what needs to be done as opposed to what can be done, and the risks of not publishing because a difficult problem has been taken on. Much cancer research is irrelevant. The real problem is metastasis, but lacking good models, we have used irrelevant ones, such as tail vein injections and drug development models based on primary tumors.